ISRCTN10466893已完成1 期
A phase I study to assess the effect of three single ascending doses of sildenafil citrate oral film compared with placebo on blood pressure in healthy young and elderly male volunteers
IBSA Institut Biochimique (Switzerland)0 个研究点目标入组 26 人开始时间: 2022年11月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Informed consent: signed written informed consent before inclusion in the study
- •2. Sex and Age: males, 18-45 inclusive (young) versus =65 (elderly) years old
- •3. Body Mass Index: 18.5-30 kg/m2 inclusive
- •4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position
- •5. Full comprehension: the ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to cooperate with the Investigator and to comply with the requirements of the entire study
排除标准
- •1. Electrocardiogram (12-lead ECG in supine position): clinically significant abnormalities
- •2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study; presence or history (within 28 days) of any tongue piercings
- •3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness
- •4. Allergy: ascertained or presumptive hypersensitivity to the active principle (PDE5 inhibitors) and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
- •5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine or neurological diseases that may interfere with the aim of the study; history of vision or hearing problems related to drugs of the PDE5 inhibitor pharmacological class; history of priapism; anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease); history of ophthalmologic diseases like non-arteritic anterior ischemic optic neuropathy or retinitis pigmentosa
- •6. Medications: medications, including over-the-counter medications and herbal remedies for 2 weeks before the screening visit
- •7. Nitrates: treatment with nitrates for 2 weeks before the screening visit
- •8. Investigative drug studies: participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study
- •9. Blood donation: blood donations for 3 months before this study
- •10. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>2 drinks/day, defined according to the USDA Dietary Guidelines 2015-2020], caffeine (>5 cups coffee/tea/day) or tobacco abuse (?10 cigarettes/day)
- •11. Drug test: positive result at the drug test at screening or day-1
- •12. Alcohol test: positive alcohol breath test at day -1
- •13. Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians
研究者
相似试验
已完成
2 期
A phase 2b Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients with Knee Osteoarthritisdamaged cartilageKnee arthrosis10023213NL-OMON47160CHRU Montpellier15
已完成
1 期
The effect of DSP-2230/placebo on renal functioISRCTN02543559Sunovion Pharmaceuticals Europe Ltd (UK)44
已完成
不适用
euprolide acetate 3 month depot medicine use in advance prostate cancerCTRI/2021/07/034710Bharat Serums and Vaccines ltd8
已完成
3 期
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphomalymphomaNL-OMON47490HOVO460
进行中（未招募）
1 期
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphomadiffuse large B-cell lymphomaEUCTR2006-005174-42-NLHOVON Foundation600